Prognostic Significance of CXCL5 Expression in Cancer Patients: a Meta-analysis

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2018 May 11

PMID 29743818

Citations 33

Authors

Binwu Hu

Huiqian Fan

Xiao Lv

Songfeng Chen

Zengwu Shao

Affiliations

Soon will be listed here.

Abstract

Background: CXCL5 is a member of the CXC-type chemokine family, which has been found to play important roles in tumorigenesis and cancer progression. Recent studies have demonstrated that CXCL5 could serve as a potential prognostic biomarker for cancer patients. However, the prognostic value of CXCL5 is still controversial.

Methods: We systematically searched PubMed, Embase and Web of Science to obtain all relevant articles investigating the prognostic significance of CXCL5 expression in cancer patients. Hazards ratios (HR) with corresponding 95% confidence intervals (CI) were pooled to estimate the association between CXCL5 expression levels with survival of cancer patients.

Results: A total of 15 eligible studies including 19 cohorts and 5070 patients were enrolled in the current meta-analysis. Our results demonstrated that elevated expression level of CXCL5 was significantly associated with poor overall survival (OS) (pooled HR 1.70; 95% CI 1.36-2.12), progression-free survival (pooled HR 1.65; 95% CI 1.09-2.49) and recurrence-free survival (pooled HR 1.49; 95% CI 1.15-1.93) in cancer patients. However, high or low expression of CXCL5 made no difference in predicting the disease-free survival (pooled HR 0.63; 95% CI 0.11-3.49) of cancer patients. Furthermore, we found that high CXCL5 expression was associated with reduced OS in intrahepatic cholangiocarcinoma (HR 1.91; 95% CI 1.31-2.78) and hepatocellular carcinoma (HR 1.87; 95% CI 1.55-2.27). However, there was no significant association between expression level of CXCL5 with the OS in lung cancer (HR 1.25; 95% CI 0.79-1.99) and colorectal cancer (HR 1.16; 95% CI 0.32-4.22, p = 0.826) in current meta-analysis.

Conclusions: In conclusion, our meta-analysis suggested that elevated CXCL5 expression might be an adverse prognostic marker for cancer patients, which could help the clinical decision making process.

Citing Articles

CXCL5 Promotes the Malignant Phenotype of Pancreatic Cancer and Is Associated With Immune Infiltration.

Wang T, Sheng J, Wang X, Zhu M, Li S, Shen Y Clin Med Insights Oncol. 2024; 18:11795549241271691.

PMID: 39211563 PMC: 11359438. DOI: 10.1177/11795549241271691.

Beyond the barrier: the immune-inspired pathways of tumor extravasation.

Di Russo S, Liberati F, Riva A, Di Fonzo F, Macone A, Giardina G Cell Commun Signal. 2024; 22(1):104.

PMID: 38331871 PMC: 10851599. DOI: 10.1186/s12964-023-01429-1.

A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.

Khan S, Das T, Chakraborty S, Choudhury A, Karim H, Mostofa M Heliyon. 2023; 9(10):e21058.

PMID: 37876438 PMC: 10590981. DOI: 10.1016/j.heliyon.2023.e21058.

CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.

Zajkowska M, Dulewicz M, Kulczynska-Przybik A, Safiejko K, Juchimiuk M, Konopko M Sci Rep. 2023; 13(1):17688.

PMID: 37848726 PMC: 10582048. DOI: 10.1038/s41598-023-45093-4.

Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma.

Sari B, Gulbey O, Hamill K Front Cell Dev Biol. 2023; 11:1242706.

PMID: 37779898 PMC: 10540629. DOI: 10.3389/fcell.2023.1242706.

References

Han N, Yuan X, Wu H, Xu H, Chu Q, Guo M . DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget. 2015; 6(8):5877-88. PMC: 4467408. DOI: 10.18632/oncotarget.3463. View

Allavena P, Germano G, Marchesi F, Mantovani A . Chemokines in cancer related inflammation. Exp Cell Res. 2010; 317(5):664-73. DOI: 10.1016/j.yexcr.2010.11.013. View

Imai Y, Kubota Y, Yamamoto S, Tsuji K, Shimatani M, Shibatani N . Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol. 2005; 20(2):287-93. DOI: 10.1111/j.1440-1746.2004.03575.x. View

Speetjens F, Kuppen P, Sandel M, Menon A, Burg D, van de Velde C . Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res. 2008; 14(8):2276-84. DOI: 10.1158/1078-0432.CCR-07-4045. View

Kowalczuk O, Burzykowski T, Niklinska W, Kozlowski M, Chyczewski L, Niklinski J . CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour Biol. 2014; 35(5):4619-28. PMC: 4009141. DOI: 10.1007/s13277-014-1605-x. View

Shi D, Wu F, Gao F, Qing X, Shao Z . Prognostic value of long non-coding RNA CCAT1 expression in patients with cancer: A meta-analysis. PLoS One. 2017; 12(6):e0179346. PMC: 5464649. DOI: 10.1371/journal.pone.0179346. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Allen S, Crown S, Handel T . Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007; 25:787-820. DOI: 10.1146/annurev.immunol.24.021605.090529. View

Altman D, McShane L, Sauerbrei W, Taube S . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. PMC: 3362085. DOI: 10.1371/journal.pmed.1001216. View

10.

Ehling J, Tacke F . Role of chemokine pathways in hepatobiliary cancer. Cancer Lett. 2015; 379(2):173-83. DOI: 10.1016/j.canlet.2015.06.017. View

11.

Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J . Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils. Clin Exp Allergy. 2003; 33(4):531-7. DOI: 10.1046/j.1365-2222.2003.01609.x. View

12.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

13.

Sallusto F, Mackay C, Lanzavecchia A . The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000; 18:593-620. DOI: 10.1146/annurev.immunol.18.1.593. View

14.

Okabe H, Beppu T, Ueda M, Hayashi H, Ishiko T, Masuda T . Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. Int J Cancer. 2012; 131(10):2234-41. DOI: 10.1002/ijc.27496. View

15.

Mellado M, Rodriguez-Frade J, Manes S, Martinez-A C . Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol. 2001; 19:397-421. DOI: 10.1146/annurev.immunol.19.1.397. View

16.

Strieter R, Burdick M, Gomperts B, Belperio J, Keane M . CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005; 16(6):593-609. DOI: 10.1016/j.cytogfr.2005.04.007. View

17.

Li L, Xu L, Yan J, Zhen Z, Ji Y, Liu C . CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015; 34:129. PMC: 4621872. DOI: 10.1186/s13046-015-0247-1. View

18.

Wente M, Keane M, Burdick M, Friess H, Buchler M, Ceyhan G . Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 2006; 241(2):221-7. DOI: 10.1016/j.canlet.2005.10.041. View

19.

Samarendra H, Jones K, Petrinic T, Silva M, Reddy S, Soonawalla Z . A meta-analysis of CXCL12 expression for cancer prognosis. Br J Cancer. 2017; 117(1):124-135. PMC: 5520200. DOI: 10.1038/bjc.2017.134. View

20.

Lazennec G, Richmond A . Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010; 16(3):133-44. PMC: 2840699. DOI: 10.1016/j.molmed.2010.01.003. View